A first‐in‐human oral dose study of mesdopetam (IRL790) to assess its safety, tolerability, and pharmacokinetics in healthy male volunteers

Abstract The management of Parkinson's disease (PD) is frequently compromised by complications induced by dopaminergic treatment such as involuntary movements (dyskinesias) and psychosis. Mesdopetam (IRL790) is a novel dopamine D3 receptor antagonist developed for the management of complication...

Full description

Bibliographic Details
Main Authors: Folke Sjöberg, Susanna Waters, Boel Löfberg, Clas Sonesson, Nicholas Waters, Joakim Tedroff
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Pharmacology Research & Perspectives
Subjects:
Online Access:https://doi.org/10.1002/prp2.792